Together, we can transform the future of skin cancer care

Skin cancer is the most common cancer in the United States, with 1 in every 5 Americans estimated to develop the disease in their lifetime. With support from donors, MSK is pioneering innovations that enhance our understanding of skin cancer and lead to more skin cancer treatment breakthroughs.

Donate now

Give in honor or memory

MSK’s Veronica Rotemberg MD, PhD, smiles while in conversation with another person. A monitor showing images of skin cancer is behind her.

Your support fuels breakthroughs

Thanks to donors, MSK is a leader in skin cancer research and care. U.S. News & World Report ranked us as the #2 cancer hospital in the country, and Charity Navigator gave us its highest rating.

We’ve made considerable progress in skin cancer research and care

MSK researchers were pioneers in developing immunotherapy drugs called checkpoint inhibitors, which can be used to treat advanced melanoma — one of the most serious forms of skin cancer. These treatments have significantly improved survival and quality of life for people worldwide.

And we’re creating even more hope for tomorrow

With support from MSK Giving donors, doctors and scientists are continuing to discover more ways to better prevent, diagnose, and treat skin cancer, such as:

Combining radiation therapy with a drug called vismodegib (Erivedge®) to improve treatment efficacy and long-term survival in people with advanced basal cell carcinoma.
Maintaining a vast biospecimen database and sequencing samples with MSK-IMPACT® to learn more about skin cancer and develop better therapies.

Fund the next discovery in skin cancer research and care. You can also donate in honor or memory of a loved one.

Donate now

Fueling progress, together

MSK surgeon and researcher Charlotte Ariyan, MD, PhD, Carol Bassok Lowenstein Endowed Chair.

Sephora has generously given more than $6 million to MSK to accelerate skin cancer research and support the largest database of melanoma samples in the world.

Learn more

Fred’s Team runner and cancer research fundraiser Katie running the United Airlines NYC Half.

Mike and Katie joined MSK’s official running program, Fred’s Team, in 2019 to honor the memory of their cousin Chris. Since then, team Westdyk Strong has raised more than $200,000 for melanoma research at MSK.

Run with Fred’s Team

MSK melanoma patient Roberto stands on a blue track wearing a white T-shirt that says “cancer fighter” in blue lettering.

Philanthropy supported melanoma research at MSK that led to the discovery of a new class of immunotherapy called TIL therapy, which helped Roberto after his metastatic melanoma stopped responding to other treatments.

Read the story

Your gift today can power the next big breakthrough

With your support, MSK can continue leading the way forward in skin cancer research and care. Learn more about MSK’s innovations and advances and the progress you fuel as an MSK Giving donor.

Decoding RAS mutations

RAS-family genetic mutations are found in many cancers, including some melanomas. MSK scientists are carefully studying these mutations to identify ways to therapeutically target them, offering promise for new treatments.

Learn more

Outsmarting cancer with AI

MSK’s Veronica Rotemberg, MD, PhD, and her team are focused not only on using AI to more accurately diagnose skin cancers but on training AI tools to be even better at detecting cancer in diverse populations.

Longtime MSK supporters Marie-Josée and Henry R. Kravis recently made a generous $40 million gift to expand immunobiology and immunotherapy research to uncover more groundbreaking treatments, including for skin cancers.

See the impact

Transform the future of skin cancer care worldwide

Donate now